Highlights
Headquartered in Australia and focused exclusively on the Asia Pacific, Novotech is internationally recognized as a leading regional full-service CRO.
With operations in Australia, New Zealand, China, Hong Kong, India, Malaysia, the Philippines, Singapore, South Africa, South Korea, Taiwan and Thailand, Novotech’s service offering has come to be recognized for its quality both by our clients, as well as industry analyst groups.
With more than 700 trials completed across most therapeutic areas, Novotech has a world of experience. And it’s that experience that sets us apart, making us one of the leading midsize clinical research organizations – not just in the Asia-Pacific region – but in the world.
Outstanding Experiences
| Oncology/Breast cancer |
PUMA |
phase III |
Novotech was engaged as the Asia Pacific regional CRO to help bring the project recruitment back on track. Despite a late start and facing rapid start-up milestones, Taiwan become the 2nd highest recruiting country globally – accounting for 40% of patients to date. |
| Nephrology/ CKD |
CKD |
phase III |
Taiwan is the 3rd highest recruiting country globally. |
| Endocrinology / Obesity |
|
Phase I/II |
Novotech was engaged as a full service CRO in a multicenter phase I/II obesity treatment research program. Novotech achieved key study milestones ahead of schedule. |
| ENT/Pharyngitis |
|
phase III |
A delayed study start meant Novotech was faced with the challenge of recruiting 320 patients in just 8 weeks, in an already difficult recruitment scenario.
Thanks to innovative recruitment techniques and collaboration with study sites, a patient recruitment campaign proved to be a success – exceeding the recruitment target within planned timelines. |
